370 related articles for article (PubMed ID: 15853526)
21. Antioxidant approaches for the treatment of Alzheimer's disease.
Lee HP; Zhu X; Casadesus G; Castellani RJ; Nunomura A; Smith MA; Lee HG; Perry G
Expert Rev Neurother; 2010 Jul; 10(7):1201-8. PubMed ID: 20586698
[TBL] [Abstract][Full Text] [Related]
22. [Secretases as therapeutic targets for the treatment of Alzheimer's disease].
Dejaegere T; de Strooper B
Verh K Acad Geneeskd Belg; 2004; 66(1):29-58; discussion 58-9. PubMed ID: 15074081
[TBL] [Abstract][Full Text] [Related]
23. Presenilin function and gamma-secretase activity.
Brunkan AL; Goate AM
J Neurochem; 2005 May; 93(4):769-92. PubMed ID: 15857382
[TBL] [Abstract][Full Text] [Related]
24. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
25. Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.
Abdul HM; Calabrese V; Calvani M; Butterfield DA
J Neurosci Res; 2006 Aug; 84(2):398-408. PubMed ID: 16634066
[TBL] [Abstract][Full Text] [Related]
26. Pathogenic mechanisms in Alzheimer's disease.
Pastorino L; Lu KP
Eur J Pharmacol; 2006 Sep; 545(1):29-38. PubMed ID: 16904664
[TBL] [Abstract][Full Text] [Related]
27. [Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?].
Checler F; Buée L
Ann Pharm Fr; 2009 Mar; 67(2):136-53. PubMed ID: 19298897
[TBL] [Abstract][Full Text] [Related]
28. Regulation of the lipidation of beta-secretase by statins.
Parsons RB; Farrant JK; Price GC; Subramaniam D; Austen BM
Biochem Soc Trans; 2007 Jun; 35(Pt 3):577-82. PubMed ID: 17511656
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies for Alzheimer's disease.
Wolfe MS
Nat Rev Drug Discov; 2002 Nov; 1(11):859-66. PubMed ID: 12415246
[TBL] [Abstract][Full Text] [Related]
30. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.
Pangalos MN; Jacobsen SJ; Reinhart PH
Biochem Soc Trans; 2005 Aug; 33(Pt 4):553-8. PubMed ID: 16042543
[TBL] [Abstract][Full Text] [Related]
31. CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production.
Zhou S; Zhou H; Walian PJ; Jap BK
Proc Natl Acad Sci U S A; 2005 May; 102(21):7499-504. PubMed ID: 15890777
[TBL] [Abstract][Full Text] [Related]
32. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma.
Craft DL; Wein LM; Selkoe DJ
Bull Math Biol; 2002 Sep; 64(5):1011-31. PubMed ID: 12391865
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease.
Hook V; Toneff T; Bogyo M; Greenbaum D; Medzihradszky KF; Neveu J; Lane W; Hook G; Reisine T
Biol Chem; 2005 Sep; 386(9):931-40. PubMed ID: 16164418
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
35. Antioxidant strategies for Alzheimer's disease.
Grundman M; Grundman M; Delaney P
Proc Nutr Soc; 2002 May; 61(2):191-202. PubMed ID: 12133201
[TBL] [Abstract][Full Text] [Related]
36. Cholesterol and Alzheimer's disease--is there a relation?
Sjögren M; Mielke M; Gustafson D; Zandi P; Skoog I
Mech Ageing Dev; 2006 Feb; 127(2):138-47. PubMed ID: 16332384
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease.
Crouch PJ; Harding SM; White AR; Camakaris J; Bush AI; Masters CL
Int J Biochem Cell Biol; 2008; 40(2):181-98. PubMed ID: 17804276
[TBL] [Abstract][Full Text] [Related]
38. The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease.
Borghi R; Patriarca S; Traverso N; Piccini A; Storace D; Garuti A; Gabriella Cirmena ; Patrizio Odetti ; Massimo Tabaton
Neurobiol Aging; 2007 Jul; 28(7):1009-14. PubMed ID: 16769154
[TBL] [Abstract][Full Text] [Related]
39. Biomedicine. Avoiding collateral damage in Alzheimer's disease treatment.
Glabe C
Science; 2006 Oct; 314(5799):602-3. PubMed ID: 17068248
[No Abstract] [Full Text] [Related]
40. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease.
Polidori MC; Griffiths HR; Mariani E; Mecocci P
Amino Acids; 2007; 32(4):553-9. PubMed ID: 17273806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
